The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): Detailed analyses from the phase III DECISION trial.
Francis P. Worden
Consultant or Advisory Role - Bayer; Onyx
Honoraria - Bayer; Onyx
Martin Fassnacht
Consultant or Advisory Role - AstraZeneca
Yuankai Shi
No relevant relationships to disclose
Tatiana Hadjieva
No relevant relationships to disclose
Francoise Bonichon
No relevant relationships to disclose
Ming Gao
No relevant relationships to disclose
Laura Fugazzola
No relevant relationships to disclose
Yuichi Ando
No relevant relationships to disclose
Yasuhisa Hasegawa
No relevant relationships to disclose
Do Joon Park
Consultant or Advisory Role - Bayer (U)
Christopher Nutting
Consultant or Advisory Role - Bayer
Steven I. Sherman
No relevant relationships to disclose
Young Kee Shong
No relevant relationships to disclose
Johannes WA Smit
No relevant relationships to disclose
John Woojune Chung
Employment or Leadership Position - Bayer
Christian Kappeler
Employment or Leadership Position - Bayer
Istvan Molnar
Employment or Leadership Position - Bayer
Martin Schlumberger
Consultant or Advisory Role - AstraZeneca; Bayer; Eisai; Genzyme
Honoraria - AstraZeneca; Bayer; Eisai; Genzyme
Research Funding - AstraZeneca; Bayer; Eisai; Genzyme
Marcia S. Brose
Consultant or Advisory Role - Bayer; Onyx
Honoraria - Bayer/Onyx
Research Funding - Bayer